Regulation of Prescription Drug Advertising: Thirty-ninth Report
United States. Congress. House. Committee on Government Operations, United States. Congress. House. Committee on Government Operations. Intergovernmental Relations Subcommittee
U.S. Government Printing Office, 1970 - Advertising - 19 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
91ST CONGRESS adver barbiturates boxed statement Bureau of Drugs Commissioner Goddard Committee on Government coordinated enforcement policy corrective Cosmetic Act criminal prosecution dandruff DBI-TD appeared Dear Doctor defective labeling Demulen Dopar Drug Advertising Division drug advertising enforcement drug advertising regulations drug advertising violations drug manufacturers Drug Safety Dyrenium evidence of effectiveness false or misleading FDA Commissioner Edwards Federal Food Federal Trade Commission Fluonid Food and Drug Government Operations guidelines for determining GUY VANDER JAGT hemolytic anemia Henry Simmons Ibid Intergovernmental Relations Subcommittee July July 17 L-Dopa marketed medical journal medical profession misbranded misleading advertising NAS/NRC panels package insert possibly effective prescribing physician prescription drug advertising promotional labeling prosecutions and seizures recommendation remedial ad remedial ads remedial letters requested a cessation requested without delay require disclosure Ritalin scription drug section 306 seizure actions Serentil side effects Simmons subcommittee investigation disclosed tion drug advertising told the subcommittee warning letters